Last reviewed · How we verify
Stool sampling
Stool sampling is a Biologic drug developed by Assistance Publique - Hôpitaux de Paris. It is currently in Phase 1 development. Also known as: Stool collection.
Stool sampling is a method used in various clinical trials to study conditions such as colorectal, lung, bladder, pancreatic, and biliary tract neoplasms. The use of stool sampling in these trials is often in conjunction with other methods, including blood sampling and ctDNA analysis, which is a type of small molecule modality.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Stool sampling |
|---|---|
| Also known as | Stool collection |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Characterization and Support of Neurodevelopmental Disorders Associated With Congenital Cardiac malfoRmations - Neonatal
- Microbiota and the Lung Cancer (NA)
- Biobank for the Identification of Biomarkers in Lung Cancer (BIRD, Biomarkers in Respiratory Disease)
- Clinico-biological Collection of Autoimmune, Dysimmune or Auto-inflammatory Dermatological Diseases
- Viromes in Infants Presenting With a Septic Syndrome (NA)
- Immune Biomarker Study for Salivary Gland Carcinoma
- Impact of Androgen Signaling on the Composition of the Immune Microenvironment in Glioblastomas (NA)
- Pesticides and Infertility: Oxidative Stress Via Circulating Cell-free DNA and Gut/Genital Microbiome Signatures in Women With Endometriosis (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Stool sampling CI brief — competitive landscape report
- Stool sampling updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI
Frequently asked questions about Stool sampling
What is Stool sampling?
Who makes Stool sampling?
Is Stool sampling also known as anything else?
What development phase is Stool sampling in?
Related
- Manufacturer: Assistance Publique - Hôpitaux de Paris — full pipeline
- Also known as: Stool collection
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing